Table 1.
Clinical characteristics of ankylosing spondylitis patients and healthy controls
| Feature | Ankylosing spondylitis patients | Control | P value |
|---|---|---|---|
| (n = 24) | (n = 11) | ||
| Mean ± SD | |||
| Age (years) at recruitment | 32.3 ± 10.5 | 35.1 ± 11.1 | 0.48 |
| Collection interval (days) | 41.0 ± 17.8 | NA | NA |
| BASDAI level | |||
| Pretreatment | 3.86 ± 0.78 | NA | <0.0001 |
| Post-treatment | 1.56 ± 0.68 | ||
| CRP level (mg/L) | |||
| Pretreatment | 31.0 ± 18.6 | NA | 0.0002 |
| Post-treatment | 6.8 ± 11.8 | ||
| No. (%) of patients | |||
| Gender | |||
| Female | 2 (8.3) | 2 (18.2) | 0.57 |
| Male | 22 (91.7) | 9 (81.8) | |
| Treatment strategy | |||
| Home | 12 (50) | NA | |
| Clinic | 12 (50) | NA | |
| Drug | |||
| Antibody | 7 (29.2) | NA | |
| Recombinant fusion protein | 17 (70.8) | NA | |
P value was estimated by comparing AS patients with controls or pretreatment with posttreatment.
BASDAI, Bath AS disease activity index; CRP, C-reactive protein; NA, not applicable.